Evotec SE: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
January 31, 2022 at 08:56 am EST
Share
DGAP Preliminary announcement financial reports: Evotec SE
/ Preliminary announcement on the disclosure of financial statements
Evotec SE: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
31.01.2022 / 14:54
Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Evotec SE hereby announces that the following financial reports shall be disclosed:
Report Type: Annual financial report of the group
Language: German
Date of disclosure: April 12, 2022
Address: https://www.evotec.com/de/investor-relations/publikationen
Language: English
Date of disclosure: April 12, 2022
Address: https://www.evotec.com/en/investor-relations/publications
Report Type: Financial report of the group (half-year/Q2)
Language: German
Date of disclosure: August 11, 2022
Address: https://www.evotec.com/de/investor-relations/publikationen
Language: English
Date of disclosure: August 11, 2022
Address: https://www.evotec.com/en/investor-relations/publications
31.01.2022 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, womenâs health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Evotec SE: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]